PMID- 31787121
OWN - NLM
STAT- MEDLINE
DCOM- 20210607
LR  - 20210607
IS  - 0317-1671 (Print)
IS  - 0317-1671 (Linking)
VI  - 47
IP  - 2
DP  - 2020 Mar
TI  - Human Leukocyte Antigen Genotype as a Marker of Multiple Sclerosis Prognosis.
PG  - 189-196
LID - 10.1017/cjn.2019.329 [doi]
AB  - OBJECTIVE: In a previous pilot monocentric study, we investigated the relation 
      between human leukocyte antigen (HLA) genotype and multiple sclerosis (MS) 
      disease progression over 2 years. HLA-A*02 allele was correlated with better 
      outcomes, whereas HLA-B*07 and HLA-B*44 were correlated with worse outcomes. The 
      objective of this extension study was to further investigate the possible 
      association of HLA genotype with disease status and progression in MS as measured 
      by sensitive and complex clinical and imaging parameters. METHODS: Hundred and 
      forty-six MS patients underwent HLA typing. Over a 4-year period of follow-up, we 
      performed three clinical and magnetic resonance imaging (MRI) assessments per 
      patient, which respectively included Expanded Disability Status Scale, Multiple 
      Sclerosis Severity Scale, Timed-25-Foot-Walk, 9-Hole Peg Test, Symbol Digit 
      Modalities Test, Brief Visual Memory Test, California Verbal Learning Test-II, 
      and whole-brain atrophy, fluid-attenuated inversion recovery (FLAIR) lesion 
      volume change and number of new FLAIR lesions using icobrain. We then compared 
      the clinical and MRI outcomes between predefined HLA patient groups. RESULTS: 
      Results of this larger study with a longer follow-up are in line with what we 
      have previously shown. HLA-A*02 allele is associated with potentially better MS 
      outcomes, whereas HLA-B*07, HLA-B*44, HLA-B*08, and HLA-DQB1*06 with a potential 
      negative effect. Results for HLA-DRB1*15 are inconclusive. CONCLUSION: In the era 
      of MS treatment abundance, HLA genotype might serve as an early biomarker for MS 
      outcomes to inform individualized treatment decisions.
FAU - Lysandropoulos, Andreas P
AU  - Lysandropoulos AP
AD  - Department of Neurology, Erasme Hospital, Universite Libre de Bruxelles, 
      Brussels, Belgium.
FAU - Perrotta, Gaetano
AU  - Perrotta G
AD  - Department of Neurology, Erasme Hospital, Universite Libre de Bruxelles, 
      Brussels, Belgium.
FAU - Billiet, Thibo
AU  - Billiet T
AD  - Icometrix, Leuven, Belgium.
FAU - Ribbens, Annemie
AU  - Ribbens A
AD  - Icometrix, Leuven, Belgium.
FAU - Du Pasquier, Renaud
AU  - Du Pasquier R
AD  - Service of Neurology, Department of Clinical Neurosciences, Lausanne University 
      Hospital and University of Lausanne, Lausanne, Switzerland.
FAU - Pot Kreis, Caroline
AU  - Pot Kreis C
AD  - Service of Neurology, Department of Clinical Neurosciences, Lausanne University 
      Hospital and University of Lausanne, Lausanne, Switzerland.
FAU - Maggi, Pietro
AU  - Maggi P
AD  - Service of Neurology, Department of Clinical Neurosciences, Lausanne University 
      Hospital and University of Lausanne, Lausanne, Switzerland.
FAU - Theaudin, Marie
AU  - Theaudin M
AD  - Service of Neurology, Department of Clinical Neurosciences, Lausanne University 
      Hospital and University of Lausanne, Lausanne, Switzerland.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Can J Neurol Sci
JT  - The Canadian journal of neurological sciences. Le journal canadien des sciences 
      neurologiques
JID - 0415227
RN  - 0 (HLA-A*02 antigen)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (HLA-B*07 antigen)
RN  - 0 (HLA-B44 Antigen)
RN  - 0 (HLA-B7 Antigen)
RN  - 0 (HLA-B8 Antigen)
RN  - 0 (HLA-DQ beta-Chains)
RN  - 0 (HLA-DQB1 antigen)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Disease Progression
MH  - Female
MH  - Genotype
MH  - HLA-A2 Antigen/genetics
MH  - HLA-B44 Antigen/genetics
MH  - HLA-B7 Antigen/genetics
MH  - HLA-B8 Antigen/genetics
MH  - HLA-DQ beta-Chains/*genetics
MH  - Histocompatibility Antigens Class I/*genetics
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis, Chronic Progressive/diagnostic imaging/drug 
      therapy/*genetics/physiopathology
MH  - Multiple Sclerosis, Relapsing-Remitting/diagnostic imaging/drug 
      therapy/*genetics/physiopathology
MH  - Prognosis
MH  - Young Adult
OTO - NOTNLM
OT  - Clinical score
OT  - HLA genotype
OT  - Magnetic resonance imaging
OT  - Multiple sclerosis
OT  - Prognostic
EDAT- 2019/12/04 06:00
MHDA- 2021/06/08 06:00
CRDT- 2019/12/03 06:00
PHST- 2019/12/04 06:00 [pubmed]
PHST- 2021/06/08 06:00 [medline]
PHST- 2019/12/03 06:00 [entrez]
AID - S0317167119003299 [pii]
AID - 10.1017/cjn.2019.329 [doi]
PST - ppublish
SO  - Can J Neurol Sci. 2020 Mar;47(2):189-196. doi: 10.1017/cjn.2019.329.